Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon-like peptide 1 in health and disease

Research output: Contribution to journalReviewResearchpeer-review

  1. From conception to infancy - early risk factors for childhood obesity

    Research output: Contribution to journalReviewResearchpeer-review

  2. Chronic endocrine consequences of traumatic brain injury - what is the evidence?

    Research output: Contribution to journalReviewResearchpeer-review

  3. Diagnosis and management of Silver-Russell syndrome: first international consensus statement

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Therapy: Liraglutide - preventing or postponing T2DM diagnosis?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  3. Renoprotection with Semaglutide and Liraglutide: Direct or Indirect Effects?

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific in obese patients with type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates insulin release and suppresses glucagon secretion in response to the ingestion of nutrients. GLP1 also delays gastric emptying and increases satiety. In patients with type 2 diabetes mellitus (T2DM), supraphysiological doses of GLP1 normalize the endogenous insulin response during a hyperglycaemic clamp. Owing to the short plasma half-life of native GLP1, several GLP1 receptor agonists (GLP1RAs) with longer half-lives have been developed for the treatment of T2DM. These compounds vary in chemical structure, pharmacokinetics and size, which results in different clinical effects on hyperglycaemia and body weight loss; these variations might also explain the difference in cardiovascular effect observed in large-scale cardiovascular outcome trials, in which certain GLP1RAs were shown to have a positive effect on cardiovascular outcomes. Owing to their metabolic effects, GLP1RAs are also considered for the treatment of several other lifestyle-induced conditions, such as obesity, prediabetes and liver disease. This Review provides insights into the physiology of GLP1 and its involvement in the pathophysiology of T2DM and an overview of the currently available and emerging GLP1RAs. Furthermore, we review the results from the currently available large-scale cardiovascular outcome trials and the use of GLP1RAs for other indications.

Original languageEnglish
JournalNature reviews. Endocrinology
Volume14
Pages (from-to)390-403
Number of pages13
ISSN1759-5029
DOIs
Publication statusPublished - May 2018

    Research areas

  • Journal Article, Review

ID: 53734239